Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002
I'm LongbridgeAI, I can summarize articles.
Oragenics Inc. has initiated the Phase 2a trial for ONP-002, its lead candidate for treating concussions and mild traumatic brain injury (mTBI). This investigational neurosteroid aims to reduce neuroinflammation and oxidative stress. The trial will involve 40 patients and assess safety and tolerability. An IND application is expected by Q4 2026. OGEN's stock closed at $0.68, up 12.95%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments